As a leading CDMO in Taiwan, Formosa Laboratories, Inc. (TWSE: 4746) has recently formed a strategic partnership with Jiksak Bioengineering, Inc. as its CDMO partner. Through this collaboration, Formosa will leverage its strong development and manufacturing capabilities to fully support Jiksak Bioengineering in advancing its innovative antibody-drug conjugate (ADC) programs toward the next key milestone.
Jiksak Bioengineering’s ADC program incorporates their proprietary neuron-selective drug delivery system (NDDS), which is designed to enable selective delivery of therapeutics to motor neurons via intravenous administration. The program is focused on treating motor neuron disease (MND) that has significant unmet medical need.
“One of the longstanding challenges in MND treatment is delivering therapeutics effectively into motor neurons,” said Nori Yumoto, Co-CEO of Jiksak Bioengineering. “Our NDDS platform enables targeted delivery of therapeutics that opens new possibilities for effective MND therapies. We believe Formosa’s development and manufacturing expertise will play an important role in translating our scientific foundation into development execution and advancing our lead ADC program toward its next key milestone.”
Through this partnership, the companies aim to accelerate the progression of the ADC candidate into clinical development.
Formosa Laboratories, Inc.
Formosa Laboratories was established as a CRO in 1995 to provide API process development, impurity identification and synthesis services, and entered GMP API manufacturing in 2000. Formosa Laboratories is located in Luzhu, Taoyuan, Taiwan, employs more than 900 people and occupies an area of 69,036 square meters. Formosa Laboratories has a wide range of manufacturing facilities, including API, High Potency API (HPAPI), Antibody-Drug conjugates (ADCs), and injectable. From the pilot plant to kilogram and tons scale manufacturing, Formosa Laboratories is well equipped with a wide range of equipment to meet the needs of different manufacturing processes and capacity to provide high quality API and Injectable. Formosa Laboratories has successfully passed GMP inspections, including Taiwan TFDA, US FDA, Europe EMA, and Japan PMDA. The company markets its products globally.
Formosa’s Japanese subsidiary, Formosa Laboratories Japan (FLJ), is responsible for product importation, sales, and regulatory affairs in Japan, while its U.S. subsidiary, Synchem-Formosa, focuses on providing CDMO services in North America.
FLJ is actively expanding its presence in the local Japanese market, serving as a key strategic bridge connecting Japan’s biotechnology industry. It provides localized importation, sales, and regulatory support. Through this setup, FLJ further integrates Formosa’s world-class CDMO capabilities with Japan’s innovative ecosystem, accelerating the development and advancement of new therapies.
Jiksak Bioengineering, Inc.
Jiksak Bioengineering, Inc., founded in 2017 and based in Kawasaki, Japan, is a pioneering biotechnology company focused on developing innovative neuron targeted drug delivery technologies. Its proprietary platform enables the development of therapies with selectivity for motor neurons, targeting neurodegenerative and neuromuscular diseases, particularly amyotrophic lateral sclerosis (ALS).
Jiksak Bioengineering’s ADC program incorporates their proprietary neuron-selective drug delivery system (NDDS), which is designed to enable selective delivery of therapeutics to motor neurons via intravenous administration. The program is focused on treating motor neuron disease (MND) that has significant unmet medical need.
“One of the longstanding challenges in MND treatment is delivering therapeutics effectively into motor neurons,” said Nori Yumoto, Co-CEO of Jiksak Bioengineering. “Our NDDS platform enables targeted delivery of therapeutics that opens new possibilities for effective MND therapies. We believe Formosa’s development and manufacturing expertise will play an important role in translating our scientific foundation into development execution and advancing our lead ADC program toward its next key milestone.”
Through this partnership, the companies aim to accelerate the progression of the ADC candidate into clinical development.
Formosa Laboratories, Inc.
Formosa Laboratories was established as a CRO in 1995 to provide API process development, impurity identification and synthesis services, and entered GMP API manufacturing in 2000. Formosa Laboratories is located in Luzhu, Taoyuan, Taiwan, employs more than 900 people and occupies an area of 69,036 square meters. Formosa Laboratories has a wide range of manufacturing facilities, including API, High Potency API (HPAPI), Antibody-Drug conjugates (ADCs), and injectable. From the pilot plant to kilogram and tons scale manufacturing, Formosa Laboratories is well equipped with a wide range of equipment to meet the needs of different manufacturing processes and capacity to provide high quality API and Injectable. Formosa Laboratories has successfully passed GMP inspections, including Taiwan TFDA, US FDA, Europe EMA, and Japan PMDA. The company markets its products globally.
Formosa’s Japanese subsidiary, Formosa Laboratories Japan (FLJ), is responsible for product importation, sales, and regulatory affairs in Japan, while its U.S. subsidiary, Synchem-Formosa, focuses on providing CDMO services in North America.
FLJ is actively expanding its presence in the local Japanese market, serving as a key strategic bridge connecting Japan’s biotechnology industry. It provides localized importation, sales, and regulatory support. Through this setup, FLJ further integrates Formosa’s world-class CDMO capabilities with Japan’s innovative ecosystem, accelerating the development and advancement of new therapies.
Jiksak Bioengineering, Inc.
Jiksak Bioengineering, Inc., founded in 2017 and based in Kawasaki, Japan, is a pioneering biotechnology company focused on developing innovative neuron targeted drug delivery technologies. Its proprietary platform enables the development of therapies with selectivity for motor neurons, targeting neurodegenerative and neuromuscular diseases, particularly amyotrophic lateral sclerosis (ALS).